Market Capital
₹3,121 Cr.
P/E
24.40
Share Price
₹ 339.0 3.45 (1.03%)
Quick View
₹ 339.0 3.45 (1.03%)
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Company Timeline

Forensics
ROE
Net Profit Margin is responsible for ROE increase over last 10 years
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
ROCE of the company has decreased even without significant capex
Pledge
Promoters have not pledged a significant portion of their holding
Working Capital
Working Capital of the company seems to be under control
Revenue Recognition
Chances of aggressive revenue recognition - Operating profit of company is not getting converted to cash and recievables rising faster than sales
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been buying the stock which is usually a sign of exuberance
Share price
Share price has increased over last 10 years due to earnings
Current vs Historic Valuation
Company is trading at a discount to 3yr historic valuations
Promoter Holding
Promoter has been buying shares from the open market over last 90 days
Debt
Company should not have issues servicing its debt
ROE
Latest
13.83%
3yr Average
14.35%
5yr Average
9.23%
Net Profit Margin
Latest
8.53%
3yr Average
8.69%
5yr Average
5.59%
ROCE
Latest
16.9%
3yr Average
19.05%
5yr Average
13.14%
Debt to Equity
Latest
0.31
3yr Average
0.3
5yr Average
0.35
Market Share
0.24% (as of Jul 22)
Anti - Diabetes - Market Share
0.99% (as of Jul 22)
Anti-Infectives - Market Share
0.60% (as of Nov 21)
Blood Related - Market Share
0.02% (as of Jul 22)
Cardiovascular - Market Share
8.90% (as of Mar 22)
Carmicide - Market Share
35.70% (as of Mar 22)
Cyclopam - Market Share
0.36% (as of Nov 21)
Dermatology - Market Share
0.82% (as of Jul 22)
Gastro-Intestinal - Market Share
0.24% (as of Nov 21)
Gynecology - Market Share
92.20% (as of Mar 22)
Homide - Market Share
69.80% (as of Mar 22)
Karvol Plus - Market Share
8.90% (as of Mar 22)
Kidodent - Market Share
2.12% (as of Nov 21)
Ophthalmology - Market Share
0.30% (as of Nov 21)
Pain - Market Share
0.60% (as of Dec 22)
Pharmaceutical Sector - Market Share
64.30% (as of Mar 22)
Renolen - Market Share
1.50% (as of Nov 21)
Respiratory - Market Share
82.40% (as of Mar 22)
Rexidin M - Market Share
55.50% (as of Mar 21)
Rexidin Plus - Market Share
97.40% (as of Mar 22)
Sensodent-K - Market Share
28.40% (as of Mar 22)
Sensodent-KF - Market Share
56.20% (as of Mar 22)
Sensoform - Market Share
35.10% (as of Mar 22)
Snowdent - Market Share
23.05% (as of Nov 21)
Stomatological - Market Share
2.45% (as of Nov 21)
Urology - Market Share
0.58% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Formulation

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • US DMF Filings (No)
    • Global DMFs filed (No)
    • Number of ANDA's Filed in USA (Nos)
    • Number of ANDA's Approved By USFDA (Nos)
    • Domestic Sales Growth - YoY (%)
    • Management Compensation as a % of Sales (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis